COVID-19 – The Appropriate place for Rapid Test Kits
In line with the recommendation of the South African National Institute for
Communicable Disease (NICD) and the recommendation of the World Health Organization (WHO),SAHPRA wishes to point out that the so-called Rapid test kits (serological test kits) that are being offered for the diagnosis of COVID-19 are not suitable for this purpose
30 March 2020
The Use of Non-Steroidal Anti-Inflammatory Drugs in patients with Covid-19
Currently, there is insufficient evidence that NSAIDs may worsen COVID-19 infection. The SAHPRA-approved professional information and patient information leaflets for NSAIDS already indicate that their anti-inflammatory effects may mask the symptoms of infections, which could delay diagnosis.
25 March 2020
MEDIA RELEASE- LAWENFORCEMENT- CAPE TOWN
The South African Health Products Regulatory Authority (SAHPRA) seized prohibited substances
13 December 2019
MEDIA RELEASE- METFORMIN_POSSIBLE CONTAMINATION WITH NDMA
The South African Health Products Regulatory Authority (SAHPRA) is investigating the possible contamination…
12 December 2019
Media Release Ranitidine containing medicines Update
Warning: Use of ranitidine-containing medicine- Update
31 October 2019
SAHPRA Final Media Release Update on Ranitidine containing Medicines
Update on recall and quarantine of ranitidine containing medicines
29 October 2019
CANNABIS AND RELATED SUBSTANCES A5 FINAL
CANNABIS AND RELATED SUBSTANCES
25 October 2019
MEDIA RELEASE- SAPS AND SAHPRA
Joint media statement issued by the South African Police Service and the South African Health Products Regulatory Authority (SAHPRA)
4 November 2019
MediaRelease-SAHPRA and SIU 19.10.19-FINAL
SAHPRA SUPPORTS THE PRESIDENT’S PROCLAMATION
19 October 2019
MediaRelease-Cannabis Licensing-HR4-FINAL
SAHPRA REFUTES THE CLAIM OF A FIRST COMMERCIAL LICENCE FOR CANNABIS
14 October 2019
MEET THE SAHPRA CEO
SAHPRA ANNOUNCES THE APPOINTMENT OF ITS NEW CHIEF EXECUTIVE OFFICER
08 October 2019
